[go: up one dir, main page]

MX2019003545A - Compuestos heterociclicos y uso de los mismos para prevenir o tratar infecciones bacterianas. - Google Patents

Compuestos heterociclicos y uso de los mismos para prevenir o tratar infecciones bacterianas.

Info

Publication number
MX2019003545A
MX2019003545A MX2019003545A MX2019003545A MX2019003545A MX 2019003545 A MX2019003545 A MX 2019003545A MX 2019003545 A MX2019003545 A MX 2019003545A MX 2019003545 A MX2019003545 A MX 2019003545A MX 2019003545 A MX2019003545 A MX 2019003545A
Authority
MX
Mexico
Prior art keywords
prevent
bacterial infections
treat bacterial
heterociclic compounds
heterociclic
Prior art date
Application number
MX2019003545A
Other languages
English (en)
Other versions
MX380865B (es
Inventor
Chasset Sophie
Chevreuil Francis
Barbion Julien
Brias Julie
Caravano Audrey
Faivre Fabien
Vomscheid Sophie
Simon Christophe
Lecointe Nicolas
Ledoussal Benoît
Richard Sébastien
Le Fralliec Géraldine
Oliveira Chrystelle
Lebel Rémi
Le-Strat Frédéric
Farescour Laurence
Original Assignee
Mutabilis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mutabilis filed Critical Mutabilis
Publication of MX2019003545A publication Critical patent/MX2019003545A/es
Publication of MX380865B publication Critical patent/MX380865B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La invención se refiere a un compuesto de fórmula (I) y un racemato, un enantiómero, un diastereoisómero, un isómero geométrico o una sal farmacéuticamente aceptable y su uso como agente antibacteriano.
MX2019003545A 2016-09-30 2017-09-29 COMPUESTOS DERIVADOS DE 1,6-DIAZABICICLO [3.2.1]OCT-3-EN-6-IL COMO INHIBIDORES DE LA ß-LACTAMASA, Y EL USO DE LOS MISMOS EN EL TRATAMIENTO DE INFECCIONES BACTERIANAS. MX380865B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306261.5A EP3301094A1 (en) 2016-09-30 2016-09-30 Heterocyclic compounds and their use in preventing or treating bacterial infections
PCT/EP2017/074873 WO2018060481A1 (en) 2016-09-30 2017-09-29 Heterocyclic compounds and their use in preventing or treating bacterial infections

Publications (2)

Publication Number Publication Date
MX2019003545A true MX2019003545A (es) 2019-06-17
MX380865B MX380865B (es) 2025-03-12

Family

ID=57130331

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003545A MX380865B (es) 2016-09-30 2017-09-29 COMPUESTOS DERIVADOS DE 1,6-DIAZABICICLO [3.2.1]OCT-3-EN-6-IL COMO INHIBIDORES DE LA ß-LACTAMASA, Y EL USO DE LOS MISMOS EN EL TRATAMIENTO DE INFECCIONES BACTERIANAS.

Country Status (24)

Country Link
US (1) US10722520B2 (es)
EP (3) EP3301094A1 (es)
JP (2) JP7089508B2 (es)
KR (1) KR102691642B1 (es)
CN (2) CN109906226B (es)
AR (1) AR109774A1 (es)
AU (1) AU2017335222C1 (es)
CA (1) CA3038221A1 (es)
CL (1) CL2019000857A1 (es)
DK (1) DK3519411T3 (es)
ES (1) ES2927528T3 (es)
HR (1) HRP20220831T1 (es)
HU (1) HUE059938T2 (es)
IL (1) IL265676B (es)
LT (1) LT3519411T (es)
MX (1) MX380865B (es)
NZ (1) NZ751859A (es)
PL (1) PL3519411T3 (es)
PT (1) PT3519411T (es)
RS (1) RS63473B1 (es)
SI (1) SI3519411T1 (es)
TW (1) TWI801353B (es)
WO (1) WO2018060481A1 (es)
ZA (1) ZA201901963B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
JP7393808B2 (ja) 2018-11-20 2023-12-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのナフチリジノン－アニリン化合物
CN113473978B (zh) 2018-11-20 2025-03-28 恩福莱克逊治疗有限公司 用于治疗皮肤疾病氰基芳烃-苯胺化合物
CA3120352A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
EP4281069A4 (en) * 2021-01-21 2025-09-17 Nflection Therapeutics Inc PROCESSES FOR THE PREPARATION OF PYRROLOPYRIDINE-ANILINE COMPOUNDS
WO2022233181A1 (en) 2021-05-07 2022-11-10 Ningxia Academy Of Agriculture And Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
GEP20094751B (en) * 2004-08-18 2009-08-10 Pfizer Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
US8138189B2 (en) 2009-03-26 2012-03-20 Hoffman-La Roche Inc. Substituted benzene compounds as modulators of the glucocorticoid receptor
TW201319068A (zh) * 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
US8791091B2 (en) * 2011-12-02 2014-07-29 Bristol-Myers Squibb Company Aryl dihydropyridinone and piperidinone MGAT2 inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
CA2875165C (en) 2012-06-04 2019-11-19 Elkimia Imino compounds as protecting agents against ultraviolet radiations
US9365526B2 (en) 2012-12-31 2016-06-14 Sun Pharmaceutical Industries Limited Process for the preparation of dasatinib and its intermediates
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
US20140315876A1 (en) * 2013-03-15 2014-10-23 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN107980000A (zh) * 2014-04-18 2018-05-01 沃克哈特有限公司 包含抗菌剂的药物组合物
HUE044061T2 (hu) * 2014-11-17 2019-09-30 Entasis Therapeutics Ltd Kombinációs terápia rezisztens bakteriális fertõzések kezelésére
CN105704828A (zh) * 2014-11-25 2016-06-22 中兴通讯股份有限公司 一种资源调度的方法和装置
TWI754613B (zh) * 2015-05-07 2022-02-11 法商木塔比利斯公司 雜環化合物及其用於預防或治療細菌感染之用途
EP3091018A1 (en) * 2015-05-07 2016-11-09 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections

Also Published As

Publication number Publication date
IL265676B (en) 2021-12-01
NZ751859A (en) 2025-09-26
CN113929680A (zh) 2022-01-14
CN109906226B (zh) 2021-11-02
PL3519411T3 (pl) 2022-08-22
ES2927528T3 (es) 2022-11-08
TW201815791A (zh) 2018-05-01
HUE059938T2 (hu) 2023-01-28
EP4086255A1 (en) 2022-11-09
JP2019530690A (ja) 2019-10-24
US10722520B2 (en) 2020-07-28
DK3519411T3 (da) 2022-07-11
AU2017335222A2 (en) 2019-05-09
JP7089508B2 (ja) 2022-06-22
AU2017335222A1 (en) 2019-04-11
JP2022097520A (ja) 2022-06-30
AU2017335222C1 (en) 2022-01-20
KR20190065326A (ko) 2019-06-11
HRP20220831T1 (hr) 2022-09-30
RU2019109177A (ru) 2020-09-30
MX380865B (es) 2025-03-12
KR102691642B1 (ko) 2024-08-05
CN109906226A (zh) 2019-06-18
EP3301094A1 (en) 2018-04-04
IL265676A (en) 2019-05-30
RU2019109177A3 (es) 2020-11-30
SI3519411T1 (sl) 2022-08-31
LT3519411T (lt) 2022-09-12
PT3519411T (pt) 2022-08-25
TWI801353B (zh) 2023-05-11
EP3519411A1 (en) 2019-08-07
CL2019000857A1 (es) 2019-08-09
EP3519411B1 (en) 2022-06-22
AU2017335222B2 (en) 2021-07-15
AR109774A1 (es) 2019-01-23
WO2018060481A1 (en) 2018-04-05
ZA201901963B (en) 2021-01-27
CA3038221A1 (en) 2018-04-05
BR112019006371A2 (pt) 2019-06-25
RS63473B1 (sr) 2022-08-31
US20190224210A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
MX2019003545A (es) Compuestos heterociclicos y uso de los mismos para prevenir o tratar infecciones bacterianas.
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CO2020000527A2 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
MX380394B (es) Compuesto novedoso de bifenilo o una sal del mismo.
UY36275A (es) Compuestos aminopirimidinilo
MX373444B (es) Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas.
AR103680A1 (es) Inhibidores selectivos de bace1
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
EA201790464A1 (ru) Гетеробициклические соединения и их применение для лечения туберкулеза
EA201890186A1 (ru) Применение штаммов микробактерий для получения антибактериальных агентов
MX2019008181A (es) Inhibidores selectivos hdac6, metodos de preparacion y aplicacion de los mismos.
EA201791219A1 (ru) Антибактериальные композиции, имеющие широкий спектр активности
CO2017001389A2 (es) Compuestos de azetidiniloxifenilpirrolidina
CO2018001237A2 (es) Derivados de apramicina efectivos contra bacterias resistentes a múltiples fármacos y composiciones de los mismos
MX2019013291A (es) Compuestos y metodos para tratar infecciones bacterianas.
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
CL2019000487A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana.
CR20180111A (es) Agentes antibacteriales que comprenden una pirazino[2,3-b] [1,4] oxazin-3-ona o un sistema de anillos relacionado
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2019010108A (es) Derivados de azetidina.
AR109409A1 (es) Compuesto de 3-piridiloxifenildihidrouracilo y su uso
AR109407A1 (es) Compuesto de 1-acetil-3-fenilurea y su uso
EA201891688A1 (ru) Адамантановое производное и его применение